Literature DB >> 7694279

Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.

I L Campbell1, C R Abraham, E Masliah, P Kemper, J D Inglis, M B Oldstone, L Mucke.   

Abstract

Cytokines are thought to be important mediators in physiologic and pathophysiologic processes affecting the central nervous system (CNS). To explore this hypothesis, transgenic mice were generated in which the cytokine interleukin 6 (IL-6), under the regulatory control of the glial fibrillary acidic protein gene promoter, was overexpressed in the CNS. A number of transgenic founder mice and their offspring exhibited a neurologic syndrome the severity of which correlated with the levels of cerebral IL-6 expression. Transgenic mice with high levels of IL-6 expression developed severe neurologic disease characterized by runting, tremor, ataxia, and seizure. Neuropathologic manifestations included neuro-degeneration, astrocytosis, angiogenesis, and induction of acute-phase-protein production. These findings indicate that cytokines such as IL-6 can have a direct pathogenic role in inflammatory, infectious, and neurodegenerative CNS diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694279      PMCID: PMC47713          DOI: 10.1073/pnas.90.21.10061

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  cDNA cloning of murine interleukin-HP1: homology with human interleukin 6.

Authors:  J Van Snick; S Cayphas; J P Szikora; J C Renauld; E Van Roost; T Boon; R J Simpson
Journal:  Eur J Immunol       Date:  1988-02       Impact factor: 5.532

2.  Nucleotide sequence of a full-length cDNA for mouse cytoskeletal beta-actin mRNA.

Authors:  K Tokunaga; H Taniguchi; K Yoda; M Shimizu; S Sakiyama
Journal:  Nucleic Acids Res       Date:  1986-03-25       Impact factor: 16.971

3.  Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system.

Authors:  F A Houssiau; K Bukasa; C J Sindic; J Van Damme; J Van Snick
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

4.  Creutzfeldt-Jacob disease: a golgi study.

Authors:  I Ferrer; F Costa; J M Grau Veciana
Journal:  Neuropathol Appl Neurobiol       Date:  1981 May-Jun       Impact factor: 8.090

Review 5.  Regulation of glial fibrillary acidic protein (GFAP) expression in CNS development and in pathological states.

Authors:  F C Chiu; J E Goldman
Journal:  J Neuroimmunol       Date:  1985-06       Impact factor: 3.478

6.  Parvalbumin in most gamma-aminobutyric acid-containing neurons of the rat cerebral cortex.

Authors:  M R Celio
Journal:  Science       Date:  1986-02-28       Impact factor: 47.728

7.  Production of hybridoma growth factor by human monocytes.

Authors:  L A Aarden; E R De Groot; O L Schaap; P M Lansdorp
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

8.  A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells.

Authors:  H Okayama; P Berg
Journal:  Mol Cell Biol       Date:  1983-02       Impact factor: 4.272

9.  Production of B cell stimulatory factor-2 and interferon gamma in the central nervous system during viral meningitis and encephalitis. Evaluation in a murine model infection and in patients.

Authors:  K Frei; T P Leist; A Meager; P Gallo; D Leppert; R M Zinkernagel; A Fontana
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

Review 10.  Molecular profile of reactive astrocytes--implications for their role in neurologic disease.

Authors:  M Eddleston; L Mucke
Journal:  Neuroscience       Date:  1993-05       Impact factor: 3.590

View more
  262 in total

1.  CNS wound healing is severely depressed in metallothionein I- and II-deficient mice.

Authors:  M Penkowa; J Carrasco; M Giralt; T Moos; J Hidalgo
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

2.  Nature of the retrograde signal from injured nerves that induces interleukin-6 mRNA in neurons.

Authors:  P G Murphy; L S Borthwick; R S Johnston; G Kuchel; P M Richardson
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

Review 3.  Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway.

Authors:  E Carla Parker-Athill; Jun Tan
Journal:  Neurosignals       Date:  2010-10-02

4.  Proinflammatory cytokine, chemokine, and cellular adhesion molecule expression during the acute phase of experimental brain abscess development.

Authors:  T Kielian; W F Hickey
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 5.  Type 2 diabetes and risk of cognitive impairment and dementia.

Authors:  Rachel A Whitmer
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

6.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

Review 7.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

Review 8.  Anti-inflammatory agents in Alzheimer's disease.

Authors:  Paul S Aisen
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

9.  Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.

Authors:  Iain L Campbell; Maria Erta; Sue Ling Lim; Ricardo Frausto; Ulrike May; Stefan Rose-John; Jürgen Scheller; Juan Hidalgo
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

Review 10.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.